ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Yahoo FinanceMay 11 20:39

ImmunityBio (IBRX.US): The 2024 Q1 financial report achieved revenue of 40,000 US dollars, the previous value was 360,000 US dollars, the expected value was 20,000 US dollars; earnings per share were -0.20 US dollars, the previous value was -0.27 dollars,

ImmunityBio (IBRX.US): The 2024 Q1 financial report achieved revenue of 40,000 US dollars, the previous value was 360,000 US dollars, the expected value was 20,000 US dollars; earnings per share were -0.20 US dollars, the previous value was -0.27 dollars, and the expected value was -0.16 US dollars.

Zhitong FinanceMay 10 17:40

ImmunityBio | 10-Q: Quarterly report

Futu NewsMay 10 05:06 · Announcements

ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment

ImmunityBio (IBRX) shares rose almost 10% in recent trading after the company shared the completion and qualification Tuesday of the drug substance for filling vials and finishing packaging enough for

MT NewswiresMay 8 02:01

Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were higher, with the Dow Jones gaining over 80 points on Tuesday.Shares of Tempur Sealy International, Inc. (NYSE:TPX) rose sharply during Tuesday's session following upbeat quarterly ear

BenzingaMay 7 22:53

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient For 170,000 Doses Of ANKTIVA

ANKTIVA Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA productImmunityBio's 400,000 square foot GMP fill-finish facility in Dunkirk,

BenzingaMay 7 20:18